PETRINI, IACOPO
 Distribuzione geografica
Continente #
NA - Nord America 6.301
EU - Europa 2.674
AS - Asia 982
AF - Africa 193
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 10.171
Nazione #
US - Stati Uniti d'America 6.142
IT - Italia 1.212
SE - Svezia 525
CN - Cina 504
BG - Bulgaria 282
DE - Germania 204
SG - Singapore 172
CI - Costa d'Avorio 166
CA - Canada 158
GB - Regno Unito 132
VN - Vietnam 101
TR - Turchia 78
FI - Finlandia 76
UA - Ucraina 59
IN - India 43
FR - Francia 37
RU - Federazione Russa 32
HK - Hong Kong 26
BE - Belgio 22
CH - Svizzera 22
AT - Austria 21
PK - Pakistan 18
SN - Senegal 17
AU - Australia 16
CZ - Repubblica Ceca 14
ID - Indonesia 11
NG - Nigeria 10
NL - Olanda 10
KR - Corea 9
ES - Italia 6
JP - Giappone 6
PL - Polonia 6
HR - Croazia 3
IE - Irlanda 3
NZ - Nuova Zelanda 3
TW - Taiwan 3
HU - Ungheria 2
IL - Israele 2
IR - Iran 2
MY - Malesia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
BR - Brasile 1
DK - Danimarca 1
EU - Europa 1
GR - Grecia 1
MK - Macedonia 1
PA - Panama 1
PH - Filippine 1
PT - Portogallo 1
SA - Arabia Saudita 1
Totale 10.171
Città #
Woodbridge 892
Ann Arbor 786
Houston 710
Fairfield 628
Chandler 416
Ashburn 384
Serra 362
Seattle 290
Sofia 281
Beijing 233
Wilmington 217
Cambridge 213
Milan 203
Abidjan 166
New York 155
Princeton 149
Ottawa 148
Florence 126
Lawrence 111
Medford 104
Pisa 98
Jacksonville 78
Izmir 74
Des Moines 72
Dearborn 68
Los Angeles 60
Nanjing 58
London 54
San Diego 46
Boardman 42
Bremen 40
Singapore 35
Dong Ket 32
Lancaster 29
Frankfurt am Main 28
Düsseldorf 27
Redwood City 24
Shenyang 24
Nanchang 23
Hong Kong 22
Westminster 22
Hebei 20
Vienna 20
Brussels 19
Washington 19
Multan 18
Bern 17
Dakar 17
Hefei 17
Rome 17
Changsha 13
Jüchen 13
Kunming 13
Ogden 13
Jiaxing 12
Lucca 12
Boulder 11
Pune 11
Lagos 10
Nuremberg 10
Olomouc 10
Tianjin 10
Vicopisano 9
Chiesina Uzzanese 8
Guangzhou 8
Phoenix 8
Grafing 6
Iowa City 6
Norwalk 6
Toronto 6
Camaiore 5
Carrara 5
Chengdu 5
Chicago 5
Columbus 5
Indiana 5
Lugo 5
Naples 5
San Jose 5
Shanghai 5
Warsaw 5
Wuhan 5
Zhengzhou 5
Alessandria 4
Cascina 4
Jakarta 4
Redmond 4
Xian 4
Zurich 4
Auburn Hills 3
Bandung 3
Boston 3
Cagliari 3
Chiavari 3
Costa Mesa 3
Hangzhou 3
Jinan 3
Lappeenranta 3
Livorno 3
Marseille 3
Totale 8.011
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 237
Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells 161
ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology 159
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC 157
MESENCHYMAL CELLS INHIBIT IL2 AND ZOLENDRONATE-INDUCED ?/d T-LYMPHOCYTES 156
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. 151
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer 150
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 144
CD57 and γδ T‐cell receptor expression in nodal metastatic spread of melanoma 141
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 137
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 136
Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.) 135
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 132
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 126
Array-based comparative genomic hybridization analysis to identify prognostic markers for resected pancreatic cancer. 125
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 124
Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? 122
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors 121
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer 121
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: A brief report 119
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 118
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies 117
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 116
The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 115
MDS: An Integrated Workup for a Correct Diagnosis 115
Growth Factor Content in Human Sera Affects the Isolation of Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow 115
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients 112
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 112
HUMAN MESENCHYMAL CELLS INHIBIT IL2 AND ZOLEDRONATE-INDUCED GAMMA/DELTA T-CELLS. 111
Human adult mesangiogenic progenitor cells reveal an early angiogenic potential, which is lost after mesengenic differentiation 111
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response 110
Oncologia 109
PET based target volume delineation in hypofractionated radiotherapy in locally advanced NSCLC: A single institution experience 109
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. 106
Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer 105
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 105
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 103
LOW RPS14 EXPRESSION IS FREQUENTLY FOUND IN NON-5Q-MYELODYSPLASTIC SYNDROMES 103
Are MSCs angiogenic cells? New insights on human nestin-positive bone marrow-derived multipotent cells 102
NUT rearrangement is uncommon in human thymic epithelial tumors 102
Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. 101
Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment 100
Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas 100
Expression and mutational status of c-kit in thymic epithelial tumors 99
Recent advances in epigenomics in NSCLC: Real-time detection and therapeutic implications 99
KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA 99
Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment 99
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup 99
Medical treatment of malignant pleural mesothelioma relapses 99
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 99
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 97
Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors 97
Thymic malignancies: From clinical management to targeted therapies 96
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 96
Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) 95
Nanotopography Induced Human Bone Marrow Mesangiogenic Progenitor Cells (MPCs) to Mesenchymal Stromal Cells (MSCs) Transition 95
Impaired function of gamma-delta lymphocytes in melanoma patients. 94
Reproducibility of the WHO classification of thymomas: Practical implications 93
Mutations of epigenetic regulatory genes are common in thymic carcinomas 93
GAMMA-DELTA T-LYMPHOCYTE SPECIFIC CLONES ARE INVOLVED IN THE GRAFT-VERSUS-MYELOMA AND IN THE GRAFT-VERSUS-HOST DISEASE IN MULTIPLE MYELOMA PATIENTS AFTER NON-MYELOABLATIVE TRANSPLANTATION. 92
OCTREOTIDE LAR SUITABLE TREATMENT FOR G1-G2 THORACIC NEUROENDOCRINE TUMORS (T-NET): SINGLE CENTER EXPERIENCE 91
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group 90
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 90
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 89
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy 88
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma 87
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer 87
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 87
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 84
COMPLETE GENOME SEQUENCING OF A HUMAN B3 THYMOMA 81
CLONOTYPE AND MUTATIONAL PATTERN IN TCRGD LARGE GRANULAR LYMPHOCYTE LEUKEMIA 81
Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation 81
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 79
Whole Genome and Transcriptome Sequencing of a B3 Thymoma 78
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer 78
Array comparative genomic hybridization of thymic epithelial tumors identifies loss of CDKN2A as a prognostic factor and BCL2 family members as targets for therapy 77
The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer 77
Myelodysplastic Syndromes: A Multidisciplinary Integrated Diagnostic Work-up for Patients' Risk Stratification 76
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 76
Biology of MET: a double life between normal tissue repair and tumor progression 73
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EOSINOPHILOIA IN EGPA FROM HES 71
Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment 70
KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA 69
ErbB in NSCLC as a molecular target: Current evidences and future directions 68
Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? 67
A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data. 67
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA 67
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma 66
Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primari tumors as predictors of activity of cetuximab plus irinotecan treatment 64
GTF2I MUTATIONS ARE FREQUENT IN THYMIC EPITHELIAL TUMORS 64
Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients. 62
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma 62
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 61
Thymectomy in myasthenic patients with thymoma: killing two birds with one stone 58
Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms 57
Thymoma: Biology 56
Next generation sequencing of thymomas and thymic carcinomas 56
Reproducibility of the WHO classification for thymomas in relation to prognosis 51
Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: A retrospective review of 22 patients 51
Hypertermic Intrathoracic Chemotherapy (HITHOC) for thymoma: a narrative review on indications and results 50
Totale 9.879
Categoria #
all - tutte 29.482
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.482


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019193 0 0 0 0 0 0 0 0 0 0 0 193
2019/20201.992 207 131 341 126 175 206 209 145 163 118 134 37
2020/2021770 57 42 39 43 53 32 66 57 97 65 85 134
2021/20221.248 32 72 20 52 232 204 42 35 71 61 71 356
2022/20231.632 207 243 112 103 144 173 22 119 329 11 156 13
2023/20241.421 106 109 174 88 157 277 72 52 15 137 125 109
Totale 10.582